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Abstract  
The redox state of cellular exofacial molecules is reflected by the amount of available thiols. 
Furthermore, surface thiols can be considered as indicators of immune cell activation. One 
group of thiol containing proteins, peroxiredoxins, in particular, have been associated with 
inflammation.  
In this study, we assessed surface thiols of the U937 and THP1 monocyte cell lines and 
primary monocytes in vitro upon inflammatory stimulation by irreversibly labelling the cells 
with a fluorescent derivative of maleimide. We also investigated exofacial thiols on 
circulating blood mononuclear cells in patients with rheumatoid arthritis and healthy controls. 
When analysing extracellular vesicles, we combined thiol labelling with the use of antibodies 
to specific CD markers to exclude extracellular vesicle mimicking signals from thiol 
containing protein aggregates. Furthermore, differential detergent lysis was applied to confirm 
the vesicular nature of the detected extracellular events in blood plasma. 
We found an increase in exofacial thiols on monocytes upon in vitro stimulation by LPS or 
TNF, both in primary monocytes and monocytic cell lines (p<0.0005). At the same time, 
newly released extracellular vesicles showed a decrease in their exofacial thiols compared 
with those from unstimulated cells (p<0.05). We also found a significant elevation of surface 
thiols on circulating monocytes in rheumatoid arthritis patients (p<0.05) and newly released 
extracellular vesicles of isolated CD14
+
 cells from rheumatoid arthritis patients had decreased 
thiol levels compared with healthy subjects (p<0.01). Exofacial peroxiredoxin 1 was 
demonstrated on the surface of primary and cultured 
1
monocytes, and the number of 
peroxiredoxin 1 positive extracellular vesicles was increased in rheumatoid arthritis blood 
plasma (p<0.05). Furthermore, an overoxidised form of peroxiredoxin was detected in 
extracellular vesicle-enriched preparations from blood plasma. 
                                                          
1
 Abbreviations: CRP: C-reactive protein, DAS: disease activity score, DTNB: 5,5-dithiobis-(2-nitrobenzoic acid), EF thiol: 
exofacial thiol, EV: extracellular vesicle, HS: healthy subject, LDL: Low-density lipoprotein, LPS: lipopolysaccharide, Mal: 
maleimide, PBMC: peripheral blood mononuclear cells, PBS: phosphate buffered saline, PDI: protein disulfide isomerase, 
PFP: platelet-free plasma, Prdx 1: peroxiredoxin 1, PVDF: polyvinylidene difluoride, RA: rheumatoid arthritis, SDS-PAGE: 
polyacrylamide gel electrophoresis, TNF: tumor necrosis factor 
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Our data show that cell surface thiols play a protective role and reflect oxidative stress 
resistance state in activated immune cells. Furthermore, they support a role of extracellular 
vesicles in the redox regulation of human monocytes, possibly representing an antioxidant 
mechanism. 
2
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Introduction  
Redox homeostasis is essential for the maintenance of cell physiology. This homeostasis is 
maintained not only by intracellular, but also by extracellular and cell surface redox molecular 
mechanisms. However, plasma membrane surface redox mechanisms received relatively little 
attention in the past. Immune reactions are characterised by substantial redox changes. 
Furthermore, immune cell activation and proliferation are associated with an increase in the 
levels of cell surface thiols [1]. For example, CD8
+
 T cells upregulate their surface thiols upon 
specific TCR stimulation before their cell proliferation starts [2]. This presumably serves as a 
protective mechanism to prevent the oxidation of sensitive surface proteins. A sustained 
upregulation of cell surface thiols on effector CD8
+
 T cells is also observed during viral 
infection [2]. Increase in surface thiol levels (a process dependent on cell surface protein 
disulfide isomerase) is also necessary for increased proliferation of human lymphocytes [3]. 
Importantly, the increase in surface thiol levels may even enhance disease susceptibility (as 
evidenced for example in Dark Agouti rats in which it has been shown to enhance 
susceptibility to develop severe arthritis) [4].  
Extracellular vesicles (EVs) are phospholipid bilayer membrane enclosed subcellular 
structures released by all types of cells [5, 6]. EVs are characterised by substantial 
heterogeneity; the best characterised categories include exosomes (30-150 nm), 
microvesicles/microparticles (100-1000 nm) and large EVs such as apoptotic bodies 
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(>1000m) [5, 6]. 
A role for thiol groups in extracellular vesicle (EV) release has been first demonstrated when 
Dachary-Pringent and colleagues showed that blocking of thiols prevented 
microparticle/microvesicle release by platelets [7]. Other studies also showed a link between 
redox processes and EV release (reviewed in [8]).  
The role of extracellular vesicles (EVs) in arthritis has been increasingly recognised [6]. 
However, the redox state and redox aspects of EVs in RA have not yet been studied.  
In this paper, we detect for the first time the levels of EV thiols in a releasing cell type-
specific manner. Furthermore, we show a decrease in surface thiol levels of freshly released 
EVs, in sharp contrast with the elevation of surface thiols of the activated mother cells. Based 
on these data, we propose that activated cells use EV-secretion as a tool to rapidly enhance 
their plasma membrane thiol levels by shedding oxidised (less reduced) plasma membrane 
patches in the form of EVs.  This mechanism could possibly serve as part of the cells’ 
antioxidant defence system.) 
  
Materials and Methods 
Sample collection and subjects 
After obtaining ethics permission from the Hungarian Scientific and Research Ethics 
Committee and informed consent from the subjects, blood samples were collected from RA 
patients and healthy subjects (HS) in EDTA for monocyte isolation and detection and acid 
citrate dextrose (ACD-A) anticoagulation tubes for EV assessment (both from Greiner). 
ACD-A tubes were used to prevent in vitro vesiculation of blood cells [9]. Anticoagulated 
blood samples were centrifuged first at 400 g for 20 minutes, and then twice at 3000 g for 15 
minutes to remove platelets. The supernatant was snap frozen in liquid nitrogen and kept at -
80 
o
C in aliquots, as platelet-free plasma (PFP). Peripheral blood mononuclear cells (PBMCs) 
were isolated using Ficoll (Sigma) gradient separation. PBMCs were lysed for Western 
blotting experiments and kept at -80 
o
C.  
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Altogether, 71 patients with RA, with a median age of 59.5 years (range: 29-88 years) were 
involved in this study. The patients were treated at the Department of Rheumatology, 
Semmelweis University (Budapest, Hungary). The median DAS28 score was 3.14 (range: 0.8-
7.08) and the median CRP value was 4 mg/L (range: 0-603 mg/L). Only RA patients 
diagnosed on the basis of the American College of Rheumatology criteria [10, 11] were 
included. The median age of the 54 healthy subjects was 42 years (range: 20-71 years).  
 
Detection of cell surface thiol levels using flow cytometry 
EDTA anticoagulated whole blood (1 mL) from RA patients (n=15) and healthy subjects 
(n=10) was washed once in Hanks balanced salt solution (Sigma) and incubated in 50 μM 
DyLight-488 maleimide (ThermoFisher Scientific) for 20 minutes at room temperature. 
Subsequently, the samples were washed twice and incubated with anti-CD3-APC (BD 
Pharmingen), anti-CD11c-APC (BioLegend) / anti-CD14-APC (SONY) / anti-CD14-PerCP-
Cy5.5 (BD Biosciences) or anti-CD19-PerCP-Cy5.5 (BD Biosciences) antibodies. Following 
antibody labelling, the samples were treated with FACSLyse Solution (BD) for 10 min at 4 
o
C 
and measured using a FACSCalibur Flow Cytometer (Beckton-Dickinson). Cellquest 
software (BD Biosciences) and by FlowJo software (Treestar, Ashland, OR) were used for 
flow cytometer data analysis. 
 
In vitro stimulation of monocytes by lipopolysaccharide (LPS) and tumour necrosis 
factor (TNF) and in vitro EV collection 
Peripheral blood samples were collected from healthy subjects (n=8) in EDTA anticoagulant 
tubes. In order to avoid exposure of blood to ambient oxygen, 100 ng/mL LPS (L6529 
O55:B5 E coli Sigma) was injected with a needle and syringe directly into the Vacuette 
®
 
collection tube without abolishing vacuum, and whole blood samples were incubated for 90 
min at 37 
o
C. Following the incubation period, exofacial thiol levels of CD11c
+
/CD14
+
 
monocytes were measured as described above.  
U937 and Thp1 monocytes were seeded at 0.5-1x10
6 
cells/mL serum-free RPMI medium. The 
cells were treated with 1 μg/mL or 100 ng/mL LPS (L6529 O55:B5 E. coli Sigma) or with 10 
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ng/mL human TNF (Sigma), and were incubated for 90 min at 37 
o
C. The cells were 
subsequently washed with phosphate buffered saline (PBS), labelled with DyLight-488 
maleimide at a 25 μM concentration. After an incubation period of 15 min at 4 oC and an 
additional washing step, levels of exofacial thiols were detected using flow cytometry.  
EVs from the 90 minutes conditioned media of LPS-treated U937 monocytes were collected 
by spinning the supernatant at 300 g for 5 min, followed by 2,000 g 20 min and 20,000 g for 
40 min. The final pellet was resuspended in 40 μL PBS and incubated with 25 μM DyLight-
488 Mal for 20 min. Subsequently, the samples were washed and measured using flow 
cytometry. 
 
Isolation of CD14 positive cells from peripheral blood and collection of EV-containing 
conditioned media 
Peripheral blood monocytes from RA patients and healthy subjects were isolated with the 
EasySep Human CD14 Positive Selection Kit (Stemcell Technologies) according to the 
manufacturer’s instruction. Briefly, peripheral blood samples were collected from healthy 
subjects (n=5) and rheumatoid arthritis patients (n=6) in EDTA anticoagulated tubes. PBMCs 
were isolated using Ficoll (Sigma) gradient separation. The PBMCs were then mixed with an 
anti-CD14 antibody cocktail and specific magnetic nanoparticles. Subsequently, the mixture 
was washed and CD14
+
 cells were isolated with the aid of a magnet. Cell viability was 
assessed using trypan blue staining and only samples with more than 95 % cell viability were 
used for downstream experiments. The CD14 positivity of cells was proved using flow 
cytometry. 
Cells were then seeded at 0.5-1x10
6 
cells/mL concentration in RPMI medium containing 10% 
EV-free fetal bovine serum. After an incubation period of 90 minutes at 37 
o
C, EVs were 
collected from the supernatant by spinning the supernatant at 300 g for 5 min, followed by 
2,000 g 20 min and 16,100 g for 40 min. The final pellet was resuspended in 40 μL PBS and 
incubated with 25 μM DyLight-488 Mal for 20 minutes. Subsequently, the samples were 
washed and the thiols levels of EVs were measured with a FACSCalibur Cytometer. EV gate 
was established using Megamix (Biosytex) and silica beads (1 μm Silica Beads Fluo-Green) 
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(Kisker, Steinfurt, Germany) as we described earlier [12, 13]. After recording, samples were 
treated with 0.1 % Triton X-100 and only Triton-sensitive events were considered genuine 
EVs [12].  
 
Detection of thiol levels in human blood plasma using an Ellman’s assay 
PBS (80 μL) was added to plasma samples (100 μL) in the wells of a 96 well plate (Nunc, 
ThermoFisher Scientific). Next, 20 μL 10 mM 5,5-dithiobis-(2-nitrobenzoic acid) (DTNB) 
reagent (Pierce) dissolved in cc. methanol, was added to each well. After an incubation period 
of 15 min at room temperature, optical densities of the wells were measured at 412 nm using a 
Labsystems Multiskan MS Spectrophotometer. For each sample, a blank was also measured, 
and its optical density was subtracted as background. A standard curve was established using 
different dilutions of a cysteine standard (Pierce) in PBS and the concentration of thiols was 
expressed as μM cysteine equivalent/100 μL blood plasma. 
 
Labelling of EVs with annexin-V, antibodies to CD markers and DyLight maleimide  
For annexin-V labelling of EVs, annexin-V-FITC or APC (BD Biosciences) (5 μL) was added 
to plasma samples (50 μL) and incubated for 5 min at room temperature. After the addition of 
1mL annexin-binding buffer (5mM CaCl2 solution in deionized water), the samples were spun 
at 20,500 g for 40 min at room temperature. The supernatant was discarded and the pellet was 
resuspended in 450 μL annexin-binding buffer. EVs were labelled using anti-CD9-FITC 
(Sigma) and anti CD-63-PE (Sigma) antibodies. EVs were also tested using antibodies to 
platelets (anti-CD41a- FITC or APC (BD Biosciences)), endothelial cells (anti-CD105-FITC, 
anti-CD144-PE and anti-CD146-PE), erythrocytes (anti-glycophorin A-FITC) and monocytes 
(anti-CD14-PE) (all from BD Biosciences). FITC and PE-labelled isotype controls were used 
(BD Biosciences). For staining with antibodies, plasma samples (5 μL) were diluted in PBS 
(45 μL) and the relevant labelled antibody (1 μL) was added. The samples were incubated for 
30 min at 4 
o
C, followed by the addition of 450 μL PBS. 
Redox-specific double labelling of plasma EVs was carried out as follows: PFP samples (20 
μL) were incubated with DyLight-488 or -633 maleimide (ThermoFisher Scientific) at a final 
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concentration of 50 μM for 10 minutes at room temperature. Following the incubation period, 
500 μL filtered (through a 0.2 μM pore size filter) PBS or annexin-binding buffer was added 
to the samples, and they were spun at 20,500 g for 40 minutes. The supernatant was discarded 
using a syringe and the dry pellet was resuspended in PBS or annexin-binding buffer (50 μL). 
Then the samples were labelled with fluorochrome-conjugated antibodies or annexin-V, as 
described above. Beads (PKH26-latex beads, Sigma) with known particle number were 
added, and the samples were analysed by flow cytometry for 60 seconds.  
Western blot analysis of peroxiredoxins  
For the detection of exofacial Prdx 1 of cultured monocytes, we isolated exofacial proteins 
from LPS-treated (100 ng/mL, 24 hours) U937 cells using a Pierce cell surface protein 
isolation kit (according to the manufacturer’s instructions). Next, the isolated cell surface 
proteins were separated on a reducing 4-20% gradient SDS-PAGE gel (ThermoFisher 
Scientific), then blotted onto a PVDF (polyvinylidene difluoride) membrane, incubated in 
1:1,000 with primary antibodies against Prdx 1 (AbFrontier) and protein disulfide isomerase 
(PDI, Cell Signalling), the latter serving as a positive control. An HRP-labelled rabbit anti 
mouse antibody (Sigma) was used as secondary antibody (1:10,000). Antibody reactivity was 
detected with enhanced chemiluminescence (ThermoFisher Scientific) and a Chemidoc 
Digital Imaging System (Bio-Rad). Lysates of healthy PBMCs were also used as a positive 
control for Prdx 1. 
For the detection of intracellular Prdx 1 in PBMCs, cells were isolated as described above, 
and the pellet was lysed in non-reducing Laemmli buffer containing 100 mM maleimide. The 
method is based on the fact that reduced Prdx 1 (where the redox active peroxidatic cysteine 
is in the thiol state) is in monomeric form while oxidised Prdx 1 is dimeric. In the dimeric 
state, the peroxidatic and resolving cysteines of two Prdx 1 molecules build a disulfide bridge. 
Non-reducing Western blotting conserves and reveals this difference in the different redox 
states [14]. Lysates containing 20 μg protein, as determined by MicroBCA (ThermoFisher 
Scientific) were resolved on a non-reducing 4-20 % gradient gel, blotted and incubated with a 
mouse antibody to Prdx 1 (AbFrontier) in 1:1,000. Membrane-bound primary antibodies were 
detected as described above.  
10 
 
To detect the oxidation state of peroxiredoxins in EV-enriched preparations of PFP, PFP was 
centrifuged for 40 min at 20,500 g, and washed subsequently with PBS. The clean pellets 
were lysed in Laemmli buffer, and equivalent protein amounts (2 μg) were resolved on a 
reducing 4-20 % gradient gel, blotted and incubated with a mouse monoclonal antibody to 
overoxidised Prdx (AbFrontier) (1:500) and membrane-bound antibodies were detected as 
described above. 
 
Detection of peroxiredoxin 1 in primary monocytes using flow cytometry 
For assessment of cells, EDTA anticoagulated whole blood (1 mL) from RA patients (n=10) 
and healthy subjects (n=14) was incubated with anti-CD14-PerCP-Cy5.5 (BD Biosciences) 
/anti-CD14-APC (SONY) and anti-Prdx 1-Alexa488 (Bioss) antibodies for 20 min. Following 
antibody labelling, the samples were treated with FACSLyse Solution (BD) for 10 min at 4 
o
C 
and measured using a FACSCalibur Flow Cytometer. For intracellular Prdx 1 labelling, cells 
were first fixed with 4% PBS-buffered paraformaldehyde and permeabilised with 0.1 % 
saponin followed by labelling with anti-CD14-PerCp-Cy5.5 antibody.  
 
Detection of peroxiredoxin 1, 2 and thioredoxin 1 on EVs using flow cytometry 
For assessment of EVs, PFP samples (100 μL) were incubated with DyLight-488 maleimide 
at a final concentration of 200 μM for 10 min at room temperature. Subsequently, 500 μL 0.2 
μm-filtered PBS was added to the samples and they were spun at 20,500 g for 40 min at room 
temperature. The pellet was resuspended in 50 μL PBS and 1 μL anti-Prdx 1-Alexa647, anti-
Prdx 2-Alexa647 (Antibodies Online), anti-Trx 1-Alexa488 (Novus Biologicals) or isotype 
control antibodies (Antibodies Online, BD Biosciences) were added. The samples were 
incubated at room temperature for 20 min. After the incubation period, 450 μL PBS and 50 
μL latex beads of known concentration were added, and the samples were analysed by flow 
cytometry as described above.  
 
Statistical analysis 
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Statistical analysis was carried out with the GraphPad Prism 6 software (GraphPad Software 
Inc.). Data were analysed with Kruskal-Wallis test, Mann-Whitney test, paired and unpaired t-
tests. Results were considered statistically significant if p <0.05. 
 
 
Results 
Inflammatory stimulation with LPS and TNF results in the upregulation of surface thiol 
levels on monocytes  
The monocytic cell lines U937 and THP1 were used to test the effect of LPS (100 ng/mL, or 1 
ug/mL) and TNF (10 ng/mL) treatments (90 minutes) on the level of cell surface thiols. In the 
case of both U937 (Figure 1 A, D) and Thp1 cells (Figure 1 B, E), exofacial thiol levels 
increased significantly upon stimulation (unpaired t-test; p<0.05 and one-way ANOVA 
p<0.001, respectively). 
We wanted to test if an elevation of exofacial thiol levels is also inducible on primary 
monocyte cells. Therefore, in an attempt to model inflammatory conditions ex vivo, we 
exposed peripheral whole blood samples from HSs (n=8) to LPS (100 ng/mL) avoiding 
exposure of the cells to ambient oxygen. After 90 minutes at 37 °C, exofacial thiol levels were 
measured. There was a significant increase in the case of LPS-treated primary monocyte 
samples compared to the control group (paired t-test, p <0.0005) (Figure 1 C, F). 
 
Monocytes from rheumatoid arthritis patients show significant elevation in the level of 
their exofacial thiols compared with monocytes from healthy subjects 
Next, we addressed the question whether monocytes from RA patients showed a difference in 
their surface thiols as compared to healthy controls. We found monocytes of RA patients to 
have statistically significantly higher levels of exofacial thiols compared with the monocytes 
of healthy subjects (p <0.05, Mann-Whitney test) (Figure 2 C, F).  
Moreover, we compared surface thiol levels of circulating blood cells in RA patients (n=15) 
and HS (n=10). Circulating CD3
+ 
T lymphocytes,
 
CD19
+
 B cells and CD11c
+
/CD14
+
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monocytes have been analysed (Figure 2 A-E) by further labelling them with a thiol-specific 
fluorescent probe. We found that monocytes had significantly higher surface thiol levels as 
compared with T lymphocytes in both HS (Figure 1D) and RA (Figure 1E) groups (Kruskal-
Wallis test, p <0.001, p<0.0001).  
 
The level of exofacial thiols on EVs freshly released by stimulated monocytes is 
decreased compared with EVs released by unstimulated monocytes 
Having demonstrated that inflammation enhances surface thiol levels on monocytic cells, we 
wanted to know if similar surface thiol changes also occur on EVs. Therefore, we used in 
vitro LPS-treated U937 monocyte cells as EV donors, and measured the levels of exofacial 
thiols in the conditioned media after a 90 min period of incubation (Figure 3A). In line with 
the finding of decreased thiol levels in RA blood plasma as compared to HS, but in contrast to 
the increasing levels of cell surface thiols upon inflammatory stimuli, levels of EVs’ exofacial 
thiols also decreased upon LPS stimulation of U937 cells (p <0.05). We also analysed this 
phenomenon in a disease-setting and isolated monocytes from RA patients (n=6) and healthy 
subjects (n=5). We collected newly released EVs from the isolated cells and measured their 
surface thiol levels. Similarly to EVs released by stimulated U937 monocyte cells, monocyte 
cells from RA patients released EVs with a lower exofacial thiol content as compared to EVs 
released from monocytes of healthy subjects (Figure 3 B) (p <0.001). 
The observed lower thiols levels of EVs released from activated monocytes (i.e. in RA 
patients, and following LPS stimulation) could potentially indicate a mechanism whereby 
activated cells release EVs low in surface thiols, thereby jettisoning less reduced (oxidised) 
plasma membrane patches. 
 
Optimisation of thiol-specific labelling of blood plasma-derived extracellular vesicles 
Next, we wanted to test if similar differences could be measured in blood plasma-derived 
EVs. Although fluorescently labelled maleimide has been proposed by a recent publication to 
serve as a pan-specific marker of EVs [15], here we found that fluorescently labelled 
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maleimide alone was not suitable for labelling plasma-derived EVs due to its large non-
specific, Triton-resistant background noise (Figure 4 A-B). As our earlier work [16] identified 
low-density lipoprotein (LDL) particles as a potential major source of EV-mimicking events 
during flow cytometric measurements of blood plasma, we used a commercial preparation of 
human LDL (Merck) at a physiological concentration (2 mg/mL) in PBS to test whether it had 
a mimicking effect in our experimental setup. We stained the LDL preparation with DyLight-
488 maleimide using the same protocol as for PFP samples. Indeed, LDL particles bound the 
thiol-reactive dye DyLight-488 maleimide. The labelled events were not removed, but in 
some cases were even increased following treatment with 0.1% Triton X-100 (Figure 4 C-D). 
This was a good indication that LDL interfered with fluorescent maleimide-labelling of 
circulating vesicles, and suggested that it was necessary to further refine the method of thiol-
detection on EVs. Therefore, after labelling plasma EVs with fluorescent maleimide, we 
washed the samples, and added anti-CD9, anti-CD41a or annexin-V, followed by another 
wash step (Figure 4 E-J). The dually labelled samples were detected using flow cytometry 
without a significant background noise. The majority of the detected double positive events 
within the EV gate disappeared after Triton lysis, proving their true vesicular nature (Figure 4 
F, H, J).  
 
Redox state of blood plasma-derived extracellular vesicles in healthy subjects and 
rheumatoid arthritis patients  
After optimising the thiol-specific fluorescent labelling of plasma EVs, we went on to test a 
range of markers that we expected could detect EVs of different cellular origins in blood 
plasma. Annexin-V and among the tested antibodies, anti-CD9 and anti-CD41a gave 
appreciable signals (Figure 5 A-C), while the rest of the antibodies detected only low numbers 
of events (not shown). Therefore, we carried on with the optimised EV double labelling 
protocol using DyLight maleimide and either anti-CD9, anti-CD41a or annexin-V. 
Differential detergent lysis by Triton was used as a control for the vesicular nature of the 
detected events. Plasma-derived EVs did not display any difference between RA patients and 
HS in the level of exofacial thiols (Figure 5 D-F). Interestingly, when measuring total plasma 
thiols (which also include EV thiols), we detected a significant decrease in the thiol levels of 
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RA plasma (Figure 5 G), suggesting oxidation and a decreased reducing power in RA. 
Although EV populations identified by annexin-V, anti-CD9 and anti-CD41a did not display 
any differences between patients and controls, our experiment where we measured the thiol 
levels of EVs dereived from isolated CD14+ cells of RA patients and HS clearly prove that 
different cell-populations produce EVs with differential thiol distribution.  
 
Exofacial peroxiredoxin 1 (Prdx 1) is present on monocytes, Prdx 1 positive EVs are 
more numerous in RA blood plasma than in healthy controls 
Based on the experiments described so far, it appeared that monocytes were able to enhance 
their surface reducing power in inflammation at the expense of the reducing power of the 
released EVs. Therefore, as a next step, we aimed to analyse the distribution of the thiol 
containing redox protein, peroxiredoxin 1, in the samples. Prdx 1 has a known role in 
inflammation and autoimmune processes [17], and is also known to be secreted into the blood 
plasma both as a soluble protein and as a protein associated with exosomes [18].  
First, we assessed the presence of Prdx1, Prdx2 or Trx1 positive EVs in plasma (Figure 6 A-
C). We found that the blood plasma of both RA patients and health subjects contained such 
EVs. There was a statistically significantly higher number of Prdx1+ EVs in RA plasma 
(Figure 6A) (Mann-Whitney test, p <0.05). This could not be attributed to a difference in the 
overall concentration of EVs (Figure 5 A-C). Therefore, we analysed this molecule in 
downstream experiments. The redox state of Prdx 1 in PBMCs from RA and healthy blood 
samples was analysed using non-reducing Western blotting. With this approach we found that 
both the reduced monomeric and the oxidised dimeric forms were present in PBMCs of both 
groups (Figure 6 D). As to the amount of intracellular Prdx 1 in monocytes, we found no 
difference between the two subject groups by flow cytometry (Figure 6 G, I). Then, we went 
on to detect exofacial Prdx 1 on monocytes. Using a cell surface protein isolation kit and 
subsequent Western blotting, we demonstrated the presence of exofacial Prdx 1 in the lysate 
of U937 cells (Figure 6 E). Furthermore, using flow cytometry, we detected exofacial Prdx 1 
on CD14 positive primary monocytes from RA and HS (Figure 6 H, J). Almost all CD14 
positive cells expressed exofacial Prdx 1 on their surface in both subject groups without a 
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significant difference between the two groups (Figure 6 H).  
We also wanted to find out more about the enzymatic potential of the EV-associated Prdxs. 
Therefore, we used an antibody specific for enzymatically inactive, overoxidised Prdxs. We 
detected overoxidised Prdx species in EV-enriched 20,500g pellet from blood plasma 
(Supplementary Figure 1), both in RA patients and HS using Western blotting (Figure 6 F). 
The fact that we could readily detect overoxidised Prdx in the EV-enriched pellet suggested 
that a large proportion of EV-associated Prdxs were in fact not active enzymatically. This 
raises the possibility that EVs function as a “waste disposal” mechanism for enzymatically 
inactive Prdxs.   
 
Discussion  
Redox processes are crucial regulators of immune responses, and the role that thiol-containing 
proteins play in cellular signalling is only beginning to be revealed [19]. Similarly, EVs have 
only recently been recognised as players of cellular communication and immune responses 
[6]. Although redox processes of EVs have been suggested to be an area of interest [20], so 
far, only a few sporadic studies have looked into the redox regulation of EVs [8].  
Here, we investigated redox aspects of monocytes as well as monocyte-derived and blood 
plasma-derived EVs. We demonstrated that monocytes displayed elevated exofacial thiol 
levels under inflammatory conditions such as upon exposure to inflammatory stimuli (LPS or 
TNF) or during a chronic inflammatory disease such as RA. Exofacial thiols have been shown 
earlier to associate with lymphocyte activation [2, 3, 21]. An increase in cell surface thiols of 
monocytes in response to certain contact sensitisers has already been demonstrated [22]. 
Moreover, this increase in cell surface thiols was suggested to result in intracellular signalling 
events leading to ER stress [22]. Importantly, proteins of the actin cytoskeletal network were 
also affected by the sensitiser [22]. Similarly, rearrangement of cytoskeletal proteins such as 
actin and myosin in response to reduction of cell surface thiol containing proteins was also 
reported [21]. In addition, EV release by platelets was inhibited by a thiol blocker [7], which 
also points to the dependence of EV release on surface thiols. Therefore, elevated exofacial 
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thiols on RA monocytes are not only markers of activation but may also be a prerequisite for 
production of EVs just like in the case of platelets [7].  
In order to analyse the surface thiol content of EVs, we introduced a new dual labelling 
approach combining a fluorescent maleimide probe with antibodies to different EV surface 
markers. We found that fluorescent maleimide alone was not suitable for the specific 
detection of plasma-derived EVs, due to a large background noise from thiol-containing 
plasma proteins/protein aggregates and LDL particles. Former publications of our group 
demonstrated that both plasma protein aggregates and LDL present major confounding factors 
in the analysis of plasma-derived EVs, and differential detergent lysis provides a tool to 
distinguish between vesicles and protein aggregates [12]. LDL particles have been shown to 
be only partially sensitive to detergent lysis [16]. Co-detection of LDL particles can be 
circumvented by the use of EV-specific markers in addition to maleimide. Here we report that 
the use of fluorescent maleimide in combination with antibodies to specific EV markers or 
annexin-V provide a powerful tool to detect the redox state of plasma EVs. When analysing 
exofacial thiols of EVs released into the blood plasma, we found no difference between RA 
patients and HS. LPS stimulation resulted in a significant increase in EV release both by 
U937 cells [23] and Thp1 cells [24]. In our experiments, upon exposure to LPS, monocytes 
reacted by increasing their plasma membrane thiols and releasing EVs with decreased surface 
thiol levels. Also, RA monocytes had higher surface thiol levels compared with healthy 
monocytes, whilst releasing EVs with a decreased exofacial thiol content. Surface thiols were 
thus associated with leukocyte activation and proliferation. There is also published 
information on the molecules involved in directing such redox regulation and their molecular 
targets [25]. For example, peroxiredoxin 2 (Prdx 2) is present on the exofacial surface of B 
and T lymphocytes and increased amounts of Prdx 2 have been associated with a Th17 T 
lymphocyte phenotype [26]. Furthermore, regulatory T cells express increased exofacial 
thioredoxin 1 levels in RA and cancer, and also upon in vitro stimulation by TNF [27]. Thus, 
cell surface thiols of these cells have been suggested to play a protective role and to confer an 
increase in oxidative stress resistance [27]. The peroxiredoxin family of proteins are known to 
be associated with inflammation and cellular activation [28], and this is particularly relevant 
in EV research since peroxiredoxins are known to be present both in the EV cargo [18, 29] 
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and as free proteins. In our previous work, Prdx 2 was identified as an upregulated redox 
protein on the surface of Th17 cells in RA patients [26]. To our knowledge, this present study 
is the first report to demonstrate the exofacial appearance of Prdx 1 on monocytes. In 
addition, we found an increased concentration of Prdx 1+ EVs in blood plasma of RA patients 
as compared to healthy controls. Soluble Prdx 1 has previously been reported to act as a 
danger signal, and recombinant Prdx 1 was shown to induce an inflammatory response in 
monocyte cells [30, 31]. Theoretically, Prdx 1 on the surface of EVs could either originate 
from the releasing cells or from soluble Prdx 1 (in the latter case possibly attached onto the 
surface of vesicles). In either case, it is possible that similarly to soluble Prdx 1, these Prdx 1+ 
EVs may serve as danger signals. However, this hypothesis needs to be tested in further 
experiments.  
As to the internal Prdx 1 cargo and redox state of EVs, we observed „overoxidised” Prdx in 
EV-enriched preparations from blood plasma. In contrast, no or very little oxeroxidised Prdx 
could be detected in PBMCs from RA patients and HS (Suppl. Figure 2.). This is in 
accordance with the observation that mainly oxidised, inactive Prdx 1 is targeted for exosomal 
release [18], and that overoxidised Prdx gets enriched in the membrane compartment [32]. In 
fact, it has been described earlier that aggregated, inactive proteins can be cleared from the 
cells by non-classical secretion [33]. In summary, it appears that EVs have an overall 
antioxidant role and may well be a marker of oxidative cellular stress.  
 
Conclusion 
In this paper, we show that labelling with fluorescent maleimide is an accurate tool to 
measure surface thiol content of blood plasma-derived EVs as long as it is used in 
combination with an EV-specific marker, such as anti-CD9 or annexin-V. Furthermore, here 
we show for the first time the exofacial appearance of Prdx 1 on monocytes. Our data suggest 
a novel anti-oxidant protective mechanism via EVs (Figure 7).  
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Figure Captions 
 
Fig. 1. Changes in surface thiol levels of monocytes upon in vitro and ex vivo stimulation 
with LPS and TNF. A) Increase in the exofacial thiol levels of U937 monocyte cells upon 
stimulation with LPS (100 ng/mL) (unpaired t test p<0.05). B) Increase in the exofacial thiol 
levels of Thp1 monocyte cells upon stimulation with LPS or TNF (one-way ANOVA with 
Dunnett’s post test, p<0.001, post-test: p<0.01). C) Increase in the surface thiol levels of 
primary monocytes stimulated with LPS in whole blood ex vivo (paired t test, p<0.0005). D), 
E), F) representative histograms of the surface thiol levels of the respective cells in the top 
panels. (untreated controls: light grey, LPS and TNF treatments: black or transparent). 
Continuous line: 100ng/mL LPS; dotted line: 1µg/mL LPS; dashed line: 10ng/mL TNF 
 
Fig. 2. CD11c
+
/CD14
+
, CD19
+
 and CD3
+
 leukocytes show significant differences in the 
level of exofacial thiols. A, B, C) Levels of surface thiols of peripheral blood T cells, B cells 
and monocytes, respectively, from healthy subjects (HS) and RA patients (RA). Mann-
Whitney test (p<0.05). D, E) Levels of surface thiols of peripheral blood cells from healthy 
subjects (D) and RA patients (E) presented as MFI of DyLight-488 Mal (arbitrary value). 
Kruskal-Wallis test with Dunn’s post test, (p<0.001, p<0.0001). F) Representative histogram 
of DyLight-488 Mal staining of monocytes from a healthy subject (light grey) and an RA 
patient (black). 
 
Fig. 3. Thiols on the surface of monocyte derived EVs ex vivo and in vitro A) U937 cells 
were incubated with 100 ng/mL LPS, and thiol levels of the released EVs were measured in 
the conditioned medium after a 90 minute period (t test, p<0.05). B) Monocytes were isolated 
from RA patients and healthy subjects and incubated for 90 minutes after which the released 
EVs’ thiol levels were measured using flow cytometry. (Mann-Whitney test, p<0.01). C) A 
representative dot-plot of the EVs released by isolated monocytes.  
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Fig.4. Representative dot-plots of RA PFP samples or LDL solution before and after the 
addition of 0.1% Triton-X100. A) and B) show single DyLight maleimide staining of PFP. 
C) and D) show single DyLight maleimide staining of LDL. E)-J) show samples labelled 
with DyLight maleimide in combination with anti-CD9 antibody, anti-CD41a antibody or 
annexin-V. 
 
Fig. 5. Thiols on the surface of EVs and in blood plasma. Single labelling of PFPs from 
RA patients and HS with anti-CD9 (A), anti-CD41a (B), and annexin-V (C), respectively. 
Dual labelling of PFPs from RA patients and HS with a fluorescent maleimide probe and anti-
CD9 (D), anti-CD41a (E) or annexin-V (F), respectively. G) Thiols in PFPs measured using 
an Ellman’s assay (Mann-Whitney test, p<0.0001).  
 
Fig. 6. Peroxiredoxin 1, 2 and thioredoxin 1 on blood plasma EVs, exofacial and 
intracellular peroxiredoxin 1 of PBMCs. A) The concentration of Prdx 1+ EVs in RA 
(n=24) and HS (n=16) plasma, detected using flow cytometry (Mann-Whitney test p<0.05). 
B) The concentration of Prdx 2+ EVs in RA (n=9) and HS (n=7) plasma, detected using flow 
cytometry. C) The concentration of Trx 1+ EVs in RA (n=6) and HS (n=6) plasma, detected 
using flow cytometry. D) PBMC lysates from RA patients (n=8) and HS (n=5) were resolved 
on non-reducing gels and detected with an anti-Prdx 1 antibody. Oxidised dimeric and 
reduced monomeric forms were equally present in both subject groups. E) The presence of 
exofacial Prdx 1 was demonstrated on U937 monocytes using a cell surface protein isolation 
kit and Western blotting. A lysate of PBMCs was used as a positive control for Prdx 1, and 
detection of protein disulfide isomerase (PDI) in the membrane extracts was used as positive 
control to confirm the presence of membrane proteins. F) The oxidation state of Prdxs in EV-
enriched pellets from blood plasma were analysed using an antibody specific for 
”overoxidised” Prdxs. G) The intracellular presence of Prdx 1 in CD14+ monocytes from RA 
(n=10) and HS (n=11) were measured by flow cytometry. H) The exofacial distribution of 
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Prdx 1 in CD14
+
 monocytes from RA (n=10) and HS (n=14) were measured by flow 
cytometry.  I) Representative histogram of an RA sample. Light grey histogram shows the 
isotype control, dark grey histogram shows intracellular staining for Prdx 1 in CD14
+
 cells. J) 
A corresponding representative histogram of a PBMC sample (from an RA patient). Light 
grey histogram shows the isotype control, dark grey histogram shows intracellular staining for 
Prdx 1 in CD14
+
 cells. 
 
Fig. 7. Proposed model for the disposal of oxidised/less reduced membrane patches and 
oxidised molecules via EVs. SH designates thiol groups on surface proteins, S-S designates 
disulfides, Prdx 1-SH stands for reduced (thiol-containing) Prdx 1 and Prdx 1-SO2 designates 
overoxidised Prdx 1 (sulphinic peroxiredoxin).  
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